Drugs / 68Ga-NEB
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04273334 | Oct 2019 → Dec 2022 | lymphatic system disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT02496013 | Jan 2014 → Dec 2017 | arteriovenous hemangioma/malformation, lymph node neoplasm, lymphedema | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NEB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496013 ↗ |
| Modality | Diagnostic / imaging agent | “Novel Albumin-Binding PET Radiotracer 68Ga-NEB” NCT02496013 ↗ |
| Route | Intravenous | “intravenous injection” NCT02496013 ↗ |